检索结果-南通市图书馆

Efficacy and safety profiles of cetuximab in Chinese patients with colorectal cancer

The Chinese-German Journal of Clinical Oncology 2009年第9期8卷 526-530页

作者： liangping xia guifang guo huijuan oiu bei zhang feifei zhou VIP Region Cancer Center Sun Yat-sen University National Laboratory of Oncology in South China Guangzhou510060 China

Objective： The aim of this study was to investigate the efficacy and safety profiles of cetuximab, the commonly used monoclonal antibody of epidermal growth factor receptor, based on Chinese patients with colorectal cancer. Methods： All the papers studied on Chinese patients with gastrointestinal cancer treated by cetuximab and found in both databases of Chinese journal database for fulltext and PubMed were collected. The commonly used efficacy index such as disease control rate （CR ＋ PR ＋ SD） and response rate （CR ＋ PR） were analyzed, and the cetuximab related side effects such acne-like rash and nail change and hypersensitivity were analyzed too. Results：（1） There were 10 original papers contained total 152 patients with gastrointestinal cancer who were the candidates to analyze the safety profiles, and contained 130 patients with colorectal cancer who were candidates to analyze the efficacy. （2） The disease control rate and response rate in the whole group was 73.5% （95% CI： 65.5%-81.5%） and 29.1% （95% CI： 20.9%-37.3%）, respectively; In first-line setting group they were 70.0% （95% CI： 55%-85%） and 41.7% （95% CI： 25.6%-57.8%）, respectively; In non-first line setting group they were 71.6% （95% CI： 61.8%-81.4%） and 23.5% （95% CI： 14.3%-32.7%）, respectively. The disease control rate between the two line-setting groups was insignificant, but the response rate between the two line-setting groups was significant （P = 0.045）. （3） The incidence of acne-like rash was 72.0% （95% CI： 64.8%-79.2%）, the degree Ⅰ-Ⅱ and degree Ⅲ-Ⅳ account for 56.0% （95% CI： 48.1%-63.9%） and 16.0% （95% CI： 10.1%-21.9%）, respectively. No treatment related death, and the hypersensitivity was under control. Conclusion： This study is the first study to summarize the data of Chinese patients with colorectal cancer treated by cetuximab-contained regimen, it showed that the monoclonal antibody was effective and safe for Chinese patients as the West patients with colorectal cancer.

关键词： Chinese patient colorectal cancer cetuximab efficacy side effects

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Short-term outcomes of cetuximab combined with standard chemotherapy as non-first line setting for patients with non-small cell lung cancer:a report of 6 cases

引用

The Chinese-German Journal of Clinical Oncology 2010年第9期9卷 502-506页

作者： Fang Wang liangping xia guifang guo huijuan Qiu feifei zhou bei zhang Li zhang State Key Laboratory of Oncology in South China Guangzhou 510060 China VIP Region Sun Yat-sen University Cancer Center Guangzhou 510060 China Department of Medical Oncology Sun Yat-sen University Cancer Center Guangzhou 510060 China

Objective:Cetuximab combined with chemotherapy has been used to treat non-small cell lung cancer (NSCLC) in recent years, most of them were first line *** study was to summarize our experiences in treating NSCLC patients with cetuximab in the non-first line ***:From October 1st 2006 to December 31st 2009, six NSCLC patients were treated with cetuximab combined standard chemotherapy as non-first line setting in Sun Yat-sen University Cancer Center, *** short-term efficacies and safeties were ***:1.A total of 18 cycles of cetuximab treatment, with a median of two cycles in the whole *** were 6 patients treated as non-first line setting, overall response rate (ORR) was 33.3% (2/6), disease control rate (DCR) was 33.3% (2/6), median time to progression (TTP) was 3.5 (3-4) months, and median OS was 18 (4-28) *** were 50% (3/6) patients occurred acne-like rash within three weeks, their ORR was 66.7% (2/3), and DCR was 66.7% (2/3), however, both of ORR and DCR in patients who didn't occurred acne-like rash were 0% (0/3), the differences of ORR, DCR between two groups were in significant different (P=0.143).*** was no treatment-associated death and no cetuximab-associated *** incidence of acne-like rash was 50% occurred within three weeks, there were two patients suffered side effects associated with ***:The data of cetuximab application in non-first line setting for patients with NSCLC were rare, and the addition of cetuximab in those population was safe.

关键词： cetuximab non-small cell lung cancer (NSCLC) efficacy safety non-first line

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Short-term efficacy of Cetuximab-contained regimen on patients with advanced gastrointestinal (noncolorectal) cancer: Experiences of 16 patients in single institute

引用

The Chinese-German Journal of Clinical Oncology 2009年第11期8卷 669-674页

作者： liangping xia guifang guo bei zhang Ruihua Xu huijuan Qiu Yuming Rong feifei zhou Fang Wang State Key Laboratory of Oncology in South China Guangzhou 510060 China VIP Region Sun Yat-sen University Cancer Center Guangzhou 510060 China Department of Medicine Sun Yat-sen Universty Cancer Center Guangzhou 510060 China

Objective： Cetuximab is an effective medicine for colorectal cancer bearing wild type Kras. However, few studies of cetuximab on patients with noncolorectal gastrointestinal cancer were available now. The aim of this study was to summarize the efficacy and safety profiles base-on the experiences of 16 patients with noncolorectal gastrointestinal cancer accepted cetuximab-contained regimens treatment. Methods： The clinical data of all patients with noncolorectal gastrointestinal cancer treated by cetuximab combined with chemotherapy and/or radiotherapy from October 1st 2006 to Jun 30th 2009 in Sun Yat-sen University Cancer Center were collected. Results：（1） A total of 16 patients enrolled, including gastric cancer, esophageal carcinoma, pancreatic cancer and cholangiocarcinoma （8, 6, 1 and 1, respectively）. The cetuximab was administered 92 cycles totally with median cycle of 4. （2） PR, SD and PD obtained in 4, 3 and 2 patients respectively in cetuximab ＋ chemotherapy group. The disease control rate, median l-rP and median OS were 77.8% （7/9）, 3.5 months and 3.5 months, respectively. （3） Both of patients in cetuximab ＋ radiotherapy group achieved PR with median TTP of 4 months and 7 months, with median OS of 14 and 28 months, respectively. （4） in evaluable patients, 3 PR obtained in first-line setting, 1 PD and 1 SD achieved in second-line setting, 2 SD and 1 PD appeared in third-line and more than third-line setting. （5） The commonly side effect was neutropenia, however, rash and hypomagnesemia were the common side effects related to cetuximab. Conclusion： Cetuximab-contained regimens show a promising disease control rate, especially in first-line setting, in patients with noncolorectal gastrointestinal cancer, and the side effects both related to cytotoxic agents and related to cetuximab itself is tolerable and manageable. Of course, more phase Ⅲ clinical trails are needed urgently.

关键词： cetuximab noncolorectal gastrointestinal cancer chemotherapy efficacy

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Neck dissection for recurrent and persistent lymph nodes of nasopharyngeal carcinoma after radiotherapy： effect and choice

引用

The Chinese-German Journal of Clinical Oncology 2009年第2期8卷 81-85页

作者： liangping xia Zongyuan Zeng Zhuming guo guifang guo bei zhang huijuan Qiu feifei zhou VIP region Cancer Center Sun Yat-sen University National Laboratory of Oncology in Southern China Guangzhou 510060 China

Objective： To investigate the best surgical mode for the patients of nasopharyngeal carcinoma with recurrent and persistent lymph nodes after radiotherapy. Methods： The clinical data of 88 patients of nasopharyngeal carcinoma with recurrent and persistent lymph nodes after radiotherapy were analyzed retrospectively. The levels of involved lymph nodes and the relationship among the levels were analyzed; the survival rate and recurrent rate of the surgical modes including radical neck dissection （RND）, modified radical neck dissection （MRND）, selective neck dissection （SND）, and lymph node resection （LNR） were analyzed; the role of postoperative radiotherapy was evaluated. Results：（1） The recurrent and persistent lymph nodes mainly located in level Ⅱ（55.6% and 58.6%, respectively）, next was level Ⅲ and rarely in level Ⅳ, Ⅴ, and Ⅰ, but the number of levels Ⅳ Ⅴ, and Ⅰ with cancer-bearing lymph nodes was relatively more than that of clinical measurement. （2） Patients with lymph nodes involved in level Ⅲ and Ⅳ, usually, have other levels involved simultaneously; the percentages were 63.6% and 88.9%, respectively. However, the lymph nodes in level Ⅱ and Ⅴ were mainly isolated. （3） The 5-year survival rate and recurrent rate of the whole group were 42.77% and 22.7%, respectively. （4） The 5-year survival rates of RND, MRND, SND, and LMR groups were 39.75%, 60.00%, 37.87%, and 44.10%, respectively; the differences were insignificant （Log-rank = 1.0, P = 0.8011）; the recurrent rate between the extensive and local surgery groups were insignificant （X^2 = 0.470, P = 0.493）. （5） The 5-year survival rates of the patients with and without postoperative radiotherapy were 39.06% and 45.26%, respectively; the difference was insignificant （Log-rank = 0.06, P = 0.8138）. Conclusion： The extensive surgery was recommended when the recurrent and persistent lymph nodes were more than one level involved or very large or immovable, otherwise, the SND should be performed and postoperative radi

关键词： nasopharyngeal carcinoma cervical lymph node neck dissection surgical modes prognosis

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

72例男性乳腺癌患者临床病理特征和预后分析

引用

中国肿瘤临床 2010年第22期37卷 1296-1299页

作者：周菲菲夏良平王曦郭桂芳戎煜明丘惠娟张蓓华南肿瘤学国家重点实验室中山大学肿瘤防治中心综合科广州市510060 华南肿瘤学国家重点实验室中山大学肿瘤防治中心乳腺科广州市510060

目的:男性乳腺癌较少见,并且其特征在全球东西方患者之间也有差异。本研究旨在基于相对比较大的样本基础上提供更为可靠的男性乳腺癌的临床病理特征及预后信息。方法:收集1969年1月至2009年3月在中山大学附属肿瘤医院经病理确诊、随访... 详细信息

目的:男性乳腺癌较少见,并且其特征在全球东西方患者之间也有差异。本研究旨在基于相对比较大的样本基础上提供更为可靠的男性乳腺癌的临床病理特征及预后信息。方法:收集1969年1月至2009年3月在中山大学附属肿瘤医院经病理确诊、随访资料齐全的72例男性乳腺癌患者的临床资料,回顾性分析男性乳腺癌临床病理特征、局部复发率、远处转移率和5年生存率。结果:1)浸润性导管癌占81.9%;ER、PR、HER-2阳性率分别为90.9%,84.8%,3.3%。2)98.5%患者以乳腺肿物为首发症状,69.8%肿物位于乳晕区。3)67.6%患者接受根治术,22.1%接受改良根治术;50.0%接受术后辅助化疗,15.3%接受新辅助化疗;19.4%接受术后放疗;44.4%患者接受内分泌治疗。4)5年总生存率为72.4%,其中Ⅰ期100%、Ⅱ期74.2%、Ⅲ期57.2%、Ⅳ期0%。5)各有12.5%患者出现局部复发和远处转移,发生局部复发和转移的中位时间分别为12个月和14个月。结论:中国男性乳腺癌以无痛性乳晕区肿块为常见首发症状,以浸润性导管癌最常见,ER、PR阳性率高而HER-2阳性率低,治疗以手术为主的包括化疗、放疗、内分泌治疗的综合治疗,预后比较好。

关键词：男性乳腺癌病理特点临床特征生存率复发率

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：